Aveo Pharmaceuticals Inc.

Clinical research in renal cell carcinoma centers on treatment strategies for disease that has progressed after prior immune checkpoint inhibitor-based therapy. The sponsor’s studies in this area examine combinations involving tivozanib and nivolumab, with attention to progression-free survival and overall survival in advanced kidney cancer.

• Tivozanib and nivolumab
• Progression-free survival
• Advanced renal cancer

The focus includes patients with previously treated metastatic renal cell carcinoma and the evaluation of combination therapy in later-line disease.